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Abstract
Increased life expectancy of persons living with HIV infection receiving antiretroviral therapy heightens the
importance of preventing and treating chronic comorbidities such as cardiovascular disease. While guidelines have
increasingly advocated more aggressive use of statins for low-density lipoprotein (LDL) cholesterol reduction, it is
unclear whether people with HIV, especially women, are receiving statins when indicated, and whether their HIV
disease is a factor in access. We assessed the cumulative incidence of statin use after an indication in the Women’s
Interagency HIV Study (WIHS), from 2000 to 2014. Additionally, we used weighted proportional hazards re-
gression to estimate the effect of HIV serostatus on the time to initiation of a statin after an indication. Cumulative
incidence of statin use 5 years after an indication was low: 38% in HIV-seropositive women and 30% in HIV-
seronegative women. Compared to HIV-seronegative women, the weighted hazard ratio for initiation of a statin for
HIV-seropositive women over 5 years was 0.94 [95% confidence interval (CI) 0.62, 1.43]. Applying the American
College of Cardiology and the American Heart Association (ACC/AHA) guidelines increased the proportion of
HIV-seropositive women with a statin indication from 16% to 45%. Clinicians treating HIV-seropositive women
should consider more aggressive management of the dyslipidemia often found in this population.
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Introduction
W ith the provision of effective antiretroviral therapy(ART), the management of HIV has shifted in part
from preventing and treating opportunistic illnesses, to pre-
venting and treating non-HIV-associated diseases associated
with aging.1–12 Such non-HIV associated conditions have
emerged as the leading causes of mortality among persons
living with HIV, and among these, cardiovascular disease
(CVD) has become a major health threat.1–5,11–16 In addition
to lifestyle risk reduction, a cornerstone of CVD prevention is
the reduction in atherogenic lipids, chiefly low-density
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lipoprotein (LDL) cholesterol, and 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG)-reductase inhibitors (i.e., statins)
are very effective in lowering LDL cholesterol.17
Use of statins by people with HIV (PWH) has increased;18–21
yet it remains unclear whether these medications are pre-
scribed equally to those with and without HIV infection
when indicated—particularly among minority women. It has
been reported that PWH are less likely to be prescribed
preventive healthcare such as statins and aspirin for CVD
prevention,22–24 and procedures after an acute myocardial
infarction,25 but published studies have included relatively
few women. Current guidelines do not differentiate indica-
tions for statin use by HIV status;17,26 yet HIV is recognized
as a risk factor for CVD.27 To what extent women with HIV
(WWH) experience barriers to preventive care for CVD is not
well understood. Furthermore, despite more recent advances
in simplifying ART regimens, PWH are often prescribed
complex medication regimens, including multiple drugs for
their HIV disease as well as any comorbid conditions.28–30
Polypharmacy in this population may be a concern for
treating physicians, and may result in undertreatment of ex-
isting comorbid conditions such as dyslipidemia. Yet, very
little research currently exists on the use of statins when in-
dicated among WWH. Using data on 4607 women followed
with semiannual visits for up to 14 years in the Women’s
Interagency HIV Study (WIHS), we evaluated the effect of
HIV status on the use of statins among women with an in-
dication for their use. We also described the use of statin
therapy when indicated in this vulnerable population, and
investigated the impact of the recent changes in national
guidelines for statin initiation among WWH.
Materials and Methods
The WIHS is a multicenter, prospective cohort of WWH
infection, and HIV-seronegative controls.31 Based in multi-
ple urban sites across the United States, the WIHS began
recruiting in 1994, and enrolled patients in three waves
(1994–1995, 2001–2002, 2011–2012). Participants complete
semiannual study visits, including an extensive interview on
medication history, behavioral risk factors, and HIV-related
outcomes. As part of a detailed medication history, partici-
pants are asked to bring in all prescribed medications, in-
cluding concomitant medications such as statins, as well as
report on all medications used since their last semiannual
study visit. Blood has been drawn for HIV and non-HIV
related lab values, including LDL cholesterol, since 2000.
Our study period includes WIHS participants between 2000
and 2014. Institutional review boards at participating WIHS
sites approve informed consent forms and study protocols,
and all participants give written informed consent.
The population of interest included women without prior
statin use who were followed for at least 1 year between
October 2000 and December 2014, and who had an indication
for the use of statin therapy based on the National Cholesterol
Education Program’s Adult Treatment Panel (ATP) III
guidelines, and who had no prior reported history of statin
use. Published in 2001 and last updated in 2004, the ATP III
guidelines focus on risk factors for coronary heart disease and
expanded the indication for statin initiation with an aim to
lower LDL cholesterol values. The ATP III guidelines rec-
ommend statin use based on the presence of coronary heart
disease or other atherosclerotic disease, diabetes mellitus, the
Framingham 10-year risk score, and the current LDL cho-
lesterol value. In 2013 a new set of guidelines for statin ini-
tiation was proposed by the American College of Cardiology
and the American Heart Association (ACC/AHA).26 These
new guidelines, which further expand the indication for statin
initiation from ATP III, have been met with controversy.32
In the primary analysis, we used the ATP III guidelines to
identify WIHS women with an indication for statin initiation,
as these were the guidelines in use for the majority of the
study period. However, we also applied the 2013 ACC/AHA
guidelines to estimate the number of women who would have
had an indication for statins if these guidelines had been in
place during the study period. Our outcome of interest was the
time to initiation of a statin after an indication according to
ATP III guidelines. The exposure of interest was HIV ser-
ostatus, measured at each WIHS visit for HIV-seronegative
participants. We excluded women who died or were lost to
follow-up before October 2000, or were missing information
on necessary covariates to determine an indication for a statin.
We also excluded women without a full year of follow-up from
the initial indication, women with reported statin use before
the first known indication, and women who acquired HIV (due
to small numbers) during the course of the study.
We calculated the unadjusted cumulative incidence of wo-
men in the cohort ever having an indication for a statin use,
using an age time scale, when applying both the ATP III and
the ACC/AHA treatment guidelines. Among women for whom
statin therapy was indicated, we estimated the effect of HIV
serostatus on the risk of statin initiation. We adjusted for
confounding and loss to follow-up through the use of inverse
probability weights, including weights for the probability of
exposure and the probability of drop out.33 The final weights
are a product of the exposure and drop out weights. We in-
cluded age, race, education, smoking, hypertension, diabetes
mellitus, baseline total cholesterol, baseline LDL cholesterol,
baseline high-density lipoprotein (HDL) cholesterol, Fra-
mingham 10-year risk score, and insurance status as covariates.
Cumulative incidence estimates were computed over the time
since the statin indication.34 We used Cox proportional hazards
regression to estimate hazard ratios and 95% confidence in-
tervals (CIs). We report unadjusted models and models using
inverse probability weights to account for baseline (measured
at the indication) covariates and drop out from the cohort.34 We
report 1-, 2-, and 5-year risk differences and risk ratios using
the inverse-probability weighted cumulative mortality curves,
and generated CIs using 200 bootstrapped resamples. To
maintain flexibility in modeling nonlinear effects of continuous
variables, we used restricted quadratic splines, with knots at the
5th, 35th, 65th, and 95th percentiles of the covariate distribu-
tion.35,36 Treatment effect heterogeneity by the Framingham
risk score was explored through stratification of main effects.
To identify characteristics of patients who did not receive
statins when indicated, we also used conditional logistic re-
gression to estimate odds ratios of not receiving a statin, using
the same adjustment set as described above. We conducted all
analyses using SAS Version 9.3 (Cary, NC).
Results
The final analysis cohort included 471 women with an
indication for a statin; its construction is detailed in Fig. 1.
From 4607 women in the WIHS cohort, we excluded 885
women who died or were lost to follow up before the start of
the follow up period in October 2000. Two hundred sixty-
nine women were missing information on total cholesterol,
HDL cholesterol, LDL cholesterol, diabetes status, or insur-
ance status and were excluded, leaving 3453 women. We
then determined the number of women who had an indication
for statin initiation using the ATP III guidelines; 581 had at
least one indication. We excluded 28 women without a full
year of follow-up, 2 women who seroconverted during the
study, and 80 women who used a statin before their indica-
tion. Characteristics for these 471 women over a total of 1628
person-years are shown in Table 1. WWH comprised 68% of
the women in our cohort. HIV-seropositive women were
older on average and more likely to be white. Educational
attainment was similar between the groups. LDL and HDL
cholesterol were also relatively similar between the two
groups. The median LDL cholesterol was 165 mg/dL among
HIV-seropositive women and 160 mg/dL among HIV-
seronegative women. Most (86%) WWH used ART, the
median CD4 cell count was 490 cells/lL, and the median
log10 HIV RNA viral load was 2.3 copies/mL, corresponding
to an undetectable viral load.
Within 5 years after an indication, 38% of WWH reported
at least one episode of statin use, while 30% of HIV-
seronegative women reported use. The unadjusted and in-
verse probability-weighted results for the effect of HIV status
on time to statin initiation after an indication for statins are
presented in Table 2. The unadjusted hazard ratio for HIV-
seropositive women compared to HIV-seronegative women
was 1.37 (95% CI 0.95, 1.97). After accounting for imbal-
ances in baseline covariates and loss to follow-up, we ob-
served essentially no difference in the uptake of statins, with
a weighted hazard ratio of 0.94 (95% CI 0.62, 1.43). The
weighted 1-year risk ratio was 0.73 (0.37, 1.76), and the 2-
year risk ratio was 0.82 (0.49, 1.34). We also stratified by
categories of the Framingham risk score (<10, ‡10 units) to
examine heterogeneity in the effect of HIV on receipt of a
statin. We again found little difference in the uptake of statins
among WWH when stratified by high and low baseline Fra-
mingham risk score, although the precision of our results was
limited by the small numbers of women with a Framingham
score of at least 10 at baseline. We report unadjusted and inverse
probability-weighted cumulative incidence of statin initiation
curves in Fig. 2. While in the unadjusted curves there is an
indication of an increase in statin initiation for HIV-seropositive
FIG. 1. Cohort flow diagram.
women, in comparison to HIV-seronegative women, the
weighted curves showed no difference between the two groups.
There were two characteristics associated with a higher odds of
not receiving a statin when indicated; women with total cho-
lesterol less than 250 mg/dL and women younger than 40, with
odds ratios of 3.02 (95% CI 1.65, 5.53) and 1.75 (95% CI 0.99,
3.11), respectively.
Applying the ACC/AHA guidelines for statin initiation to
our population more than doubled the number of women with
an indication for a statin. While 581 women had an indication
with the ATP III guidelines (including women with less than
a year of follow-up for actually initiating a statin), 1508
women had an indication with the ACC/AHA guidelines. The
prevalence of HIV-seropositive women indicated for statin
use by the ATP III guidelines was 16%, and increased to 45%
with the ACC/AHA guidelines. Similar trends were seen
among HIV-seronegative women. Figure 3 displays the pro-
portion of women with an indication, as a function of age,
when applying each set of guidelines. For both HIV-
seropositive and seronegative women, the ACC/AHA guide-
lines dramatically increased the proportion of women with a
statin indication.
Discussion
Among women with an indication for statin use, there was
no difference in the uptake of statins among HIV-seropositive
women compared to HIV-seronegative women, after ad-
justment for confounding by measured covariates. However,
it is notable that the unadjusted cumulative incidence of re-
ported statin use 5 years after an indication was relatively
low: 38% in HIV-seropositive women and 30% in HIV-
seronegative women. We also found a substantial increase in
the proportion of women with a statin indication when ap-
plying the recent 2013 ACC/AHA guidelines, in comparison
to the 2001 ATP III guidelines, with both HIV-seropositive
(16% ATP III to 45% ACC/AHA) and HIV-seronegative
(19–42%) women in our cohort.
Disparities in access to cardiovascular care may contribute
to the observed underutilization of statins in our cohort, and
more broadly, in cardiovascular care for WWH. Previous
studies have identified PWH as being less likely to receive
aspirin,22 lipid lowering therapy,23 and acute care procedures
after an acute myocardial infarction.25 However, current
reports on drug utilization are cross-sectional in nature
and include populations that are overwhelmingly male. A
strength of our contribution is the longitudinal nature of our
design and follow-up, as well as a cohort containing exclu-
sively women—a chronically understudied population in
HIV research.
Statin use has continued to increase in the general US
population, consistent with revised guidelines expanding
their indications. Using data from the National Health and
Nutrition Examination Survey from 2005 to 2010, the pro-
portion of US adults eligible for statin treatment rose from
38%, using the ATP III guidelines, to 49% with the ACC/
AHA guidelines.37 In the US Medicare population, statin use
rose from 4% in 1992, to 41% in 2008.38 However, even in
the general population, statins are prescribed less than would
be expected based on the national guidelines. In a nationwide
study of veterans with coronary heart disease in the Veterans
Health Administration, only 58% of women and 65% of men
were prescribed a statin, despite their recommended use in
such patients under both sets of guidelines.39 Our results, in
both the HIV-seropositive and seronegative groups, indicate
a much lower uptake of statins, and a potential need for in-
tervention in this population. The results in the HIV-
seronegative group suggest that socioeconomic factors may
also contribute to the lack of use of statins in this population.
Two recent reports highlight the potential for the ACC/
AHA guidelines to underestimate atherosclerotic CVD risk in
PWH.40,41 While Zanni et al. found a 2.5-fold increase in the
Table 1. Characteristics of Women at the Indication for a Statin
Characteristic
HIV-seropositive (N = 321) HIV-seronegative (N = 150)
Median (IQR) n (%) Median (IQR) n (%)
Age (years) 45 (39, 50) 43 (35, 48)
Race
Black 187 (58) 92 (61)
White 83 (26) 23 (15)
Other 51 (16) 35 (23)
Education
<12 years 111 (35) 55 (37)
12 years 94 (29) 47 (31)
>12 years 116 (36) 48 (32)
Smoking 142 (44) 95 (63)
Hypertension 156 (49) 71 (47)
LDL cholesterol (mg/dL) 165 (143, 190) 160 (142, 178)
HDL cholesterol (mg/dL) 45 (36, 55) 46 (39, 55)
Triglycerides (mg/dL) 160 (113, 224) 130 (96, 177)
CD4 cell count 490 (326, 682)
Log10 HIV RNA 2.3 (2.3, 3.2)
ART use 275 (86)
AIDS diagnosis 140 (44)
ART, antiretroviral therapy; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; RNA, ribonucleic acid.
proportion of patients indicated for a statin when applying the
ACC/AHA guidelines versus the ATP III guidelines, they
also reported that 74% of patients with high risk morphology
coronary plaques would not be indicated for statin use in
their cohort, suggesting that current recommendations may
be missing an important group of patients with clinically
significant lesions. We found similar results in our national
multicenter cohort of women; the increase was even higher
(*2.8-fold increase in the proportion indicated for a statin)
in HIV-seropositive women in our cohort. Our results, in
the context of similar results from Zanni et al., suggest that
the implementation of new guidance will likely result in
a substantially more aggressive treatment paradigm for
dyslipidemia—but that a substantial proportion of women at
risk may remain untreated.
HIV specialists are increasingly responsible for manage-
ment of chronic comorbidities such as CVD in their patients.
In one recent study, there was no difference in the proportion
of patients with access to lipid screening between providers
with more experience treating PWH and those with less ex-
perience.42 Issues of increased cardiovascular risk among
HIV patients, furthermore, are not restricted to the United
States or resource-rich countries, but are also increasingly
important in other contexts, including sub-Saharan Africa.43
Risk assessment for CVD drives much of the use of statins,
but in the setting of HIV infection, there is also increasing
interest in the use of these agents for their potential anti-
inflammatory properties, given reports of heightened im-
mune activation, inflammation,44 and rates of CVD in those
living with HIV.1–5,11–16 As additional evidence for the
benefits of statins accumulates, it can be expected that their
use in PWH will grow. While the potential for these benefits
will likely continue to drive increased statin use in WWH,
treatment decisions must also take into account the impor-
tance of maintaining adherence to ART in an aging HIV-
seropositive population likely to have continued exposure to
Table 2. Effects of HIV on Statin Initiation Among Women with an Indication for Statin Use
Indication Statin initiators Risk RD (95% CI) RR (95% CI) HR (95% CI)
1 year risk
Unadjusted
HIV-seronegative 150 12 0.08 0 1
HIV-seropositive 321 31 0.10 0.01 (-0.04, 0.08) 1.18 (0.66, 2.38)
Weighteda
HIV-seronegative 152 19 0.13 0 1
HIV-seropositive 326 30 0.09 -0.03 (-0.12, 0.05) 0.73 (0.37, 1.76)
2 year risk
Unadjusted
HIV-seronegative 150 23 0.16 0 1
HIV-seropositive 321 56 0.18 0.02 (-0.07, 0.08) 1.12 (0.68, 1.68)
Weighteda
HIV-seronegative 152 29 0.20 0 1
HIV-seropositive 326 52 0.17 -0.04 (-0.14, 0.05) 0.82 (0.49, 1.34)
5 year risk
Unadjusted
HIV-seronegative 150 40 0.30 0 1 1
HIV-seropositive 321 110 0.38 0.08 (-0.01, 0.17) 1.27 (0.97, 1.74) 1.37 (0.95, 1.97)
Weighteda
HIV-seronegative 152 52 0.38 0 1 1
HIV-seropositive 326 104 0.37 -0.01 (-0.14, 0.14) 0.97 (0.72, 1.54) 0.94 (0.62, 1.43)
5 year risk, Stratified by Framingham Risk Scoreb
<10
Unadjusted
HIV-seronegative 112 27 0.28 0 1
HIV-seropositive 253 87 0.38 0.10 (0.00, 0.20) 1.36 (0.99, 2.02)
Weighteda
HIV-seronegative 106 31 0.33 0 1
HIV-seropositive 249 79 0.36 0.03 (-0.10, 0.18) 1.08 (0.78, 1.75)
‡10
Unadjusted
HIV-seronegative 38 13 0.37 0 1
HIV-seropositive 68 23 0.41 0.04 (-0.18, 0.24) 1.12 (0.64, 1.95)
Weighteda
HIV-seronegative 46 21 0.48 0 1
HIV-seropositive 77 25 0.41 -0.07 (-0.30, 0.22) 0.86 (0.48, 1.91)
aWeighted results are adjusted for baseline variables recorded at the first visit with an indication for a statin, and include age, race,
smoking, hypertension, diabetes mellitus status, Framingham Risk Score category (<10 vs. ‡10), insurance status, total cholesterol, HDL
cholesterol, LDL cholesterol, and education.
bResults are stratified by the Framingham Risk Score (<10 vs. ‡10) at the initial statin indication.
CI, confidence interval; HR, hazard ratio; RD, risk difference; RR, risk ratio.
increasing numbers of medications.28–30 Balancing these
competing considerations will be essential for clinicians de-
ciding on treatment plans for their patients.
Our study has limitations. First, statin use was self-
reported; we did not have access to claims data to verify
prescriptions, or biomarkers to verify use. It is possible that
with access to electronic medical records or prescription
claims data, the estimated incidence of new statin use could
have been higher. Second, statin indications are not entirely
fixed covariates; it is possible that patients may lower their
cardiovascular risk through behaviors such as changes in diet
and smoking habits, or HIV-specific factors such as ART.
Third, the determination of an indication for a statin requires
information on many different conditions, including smoking,
diabetes mellitus, the presence of coronary heart disease, and
several other factors. Misclassification of any of these condi-
tions may affect the construction of our indication, and thus
our analysis cohort. However, because any one condition only
FIG. 2. Cumulative incidence of statin initiation after an indication for statin use. (A) Unadjusted. (B) Weighted.
FIG. 3. Statin indication by
age and changing guidelines.
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